Skip to content

Early-Onset Cannabis Use, Retinal Biomarkers, and Risk for Schizophrenia Preliminary Study.

D. Valenti, Holly Kailher

Clinical Therapeutics May 1, 2026 DOI: 10.1016/j.clinthera.2026.04.002 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preliminary observational study Peer reviewed
Sample size 6
Population Adolescent cannabis users (six participants, twelve eyes)
Measures IMMAD-FDT (frequency doubling virtual reality technology), optical coherence tomography (OCT)
Topics Cannabis
Key findings At undosed baseline, nine of twelve eyes from six participants fell outside the IMMAD-FDT normative database for low spatial frequency contrast sensitivity. The authors propose that retinal measures may serve as early biomarkers linking adolescent cannabis use to psychosis risk, and outline future controlled studies combining IMMAD-FDT with optical coherence tomography and facial emotion recognition testing.

Abstract

Purpose: Cannabis remains one of the most commonly used psychoactive substances among adolescents, with increasing prevalence of daily use during formative neurodevelopmental years. This preliminary study looks at changes in low spatial frequency contrast sensitivity perception using frequency doubling virtual reality technology (IMMAD-FDT). Early initiation of cannabis use-particularly before age 16-has been consistently linked to an elevated risk for schizophrenia and related psychotic disorders. The retina, as an extension of the central nervous system, offers a unique, non-invasive window into neural structure and function, with changes potentially detectable through contrast sensitivity chart testing, frequency doubling virtual visual field testing and optical coherence tomography structural imaging (OCT).

Methods: This project looked at six participants data obtained under an Advarra Institutional Review Board Approved protocol; Digital Marker of Marijuana Intoxication: Measure of Dysfunctional Retinal Ganglion Cell Response (Pro00038518). The project was funded through the National Institute of Health; Marijuana Intoxication: Roadside Tool for Law Enforcement to Measure Impaired Peripheral Vision 15PNIJ-22-GG-04417-RESS. The data of interest were from the IMMAD-FDT. We reviewed dosed and undosed data relative to the IMMAD-FDT normative database. IMMAD-FDT measures contrast sensitivity at low spatial frequencies using temporally modulated striped square targets. The targets are displayed in a commercially available virtually reality headset equipped with eye tracking, allowing for precise measurement of threshold contrast sensitivity in decibels. This approach is particularly sensitive to dysfunction in the magnocellular visual pathway and intrinsically photosensitive retinal ganglion cells (ipRGCs).

Findings: Of the six participants; 12 eyes, nine eyes were considered abnormal relative to the normative data base, at an undosed baseline.

Implications: Previous work demonstrates overlapping patterns of visual dysfunction and retinal remodeling in both schizophrenia and chronic cannabis use, including deficits in low spatial frequency contrast sensitivity, thinning or changes of the retinal nerve fiber layer, and alterations in retinal ganglion cell integrity. These functional and structural changes are also associated with impaired facial emotion recognition, a hallmark of social cognitive dysfunction in schizophrenia. This paper synthesizes current evidence and describes further investigation using virtual reality-based IMMAD-FDT and discusses how the preliminary findings may relate to future more controlled studies that would include OCT imaging to identify early retinal biomarkers in abstinent cannabis users, categorized by age of onset and frequency of use. Future research would relate the functional and structural findings with additional tests of emotion cognition/facial recognition. Findings could inform early risk stratification and preventative interventions for psychosis.

Comparable studies

Other observational and cohort studies on cannabis, most cited first.

Study Year Design Participants
High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population 2009 Case-control study n = 454
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population 2013 Observational study
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people 2000 Observational
Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline 2011 Observational cohort n = 1,923
Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... 2005 Observational cohort n = 535

Citations in the library

Explore topics